STIMMEDIUM SIGNALFINANCIAL10-K

Neuronetics (STIM) shows meaningful revenue and gross profit growth alongside reduced R&D spending and improved cash generation, while total debt rose moderately and stockholders' equity declined further.

The company's improving top-line performance and narrowing net losses suggest an operational trajectory moving toward sustainability, which aligns with the removal of the explicit "cash flow break-even in Q3 2025" forward-looking target — indicating that milestone language is no longer being actively promoted, either because it was missed or is no longer the primary narrative anchor. The shift from first-person ("we/our") to third-person ("the Company") language throughout the filing may reflect a rebranding or governance-related disclosure style change worth monitoring. Investors should weigh the meaningful reduction in R&D spending carefully, as it may be supporting near-term profitability metrics at the potential cost of longer-term product development capacity.

Comparing 2026-03-17 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

Revenue grew notably at approximately 30.5% and gross profit expanded at a healthy 33.5%, indicating improving operating leverage and commercial momentum for the NeuroStar platform. Cash and equivalents grew substantially, rising roughly 52%, while accounts receivable declined nearly 30%, together suggesting improved collections discipline; however, total debt rose approximately 19% and stockholders' equity contracted by about 19%, leaving the balance sheet in a modestly more leveraged position. Net losses narrowed and operating cash burn improved meaningfully, painting a cautiously constructive picture for investors — though the sharp reduction in R&D expense and rising interest burden of 34.3% are key variables to monitor as the company pursues self-sustainability.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+52.4%
$18.5M$28.1M

Cash position surged 52.4% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
-48.4%
$12.8M$6.6M

R&D spending cut 48.4% — could signal cost discipline or concerning reduction in innovation investment.

Interest Expense
P&L
+34.3%
$5.4M$7.3M

Interest expense surged 34.3% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
+34.3%
-$31.0M-$20.4M

Operating cash flow surged 34.3% — exceptional cash generation, highest quality earnings signal.

Gross Profit
P&L
+33.5%
$54.2M$72.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+30.5%
$40.4M$52.8M

Strong top-line growth of 30.5% — accelerating demand or successful expansion into new markets.

Accounts Receivable
Balance Sheet
-29.5%
$23.4M$16.5M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Debt
Balance Sheet
+19.3%
$55.2M$65.8M

Debt rose 19.3% — additional borrowing for investment or operations; monitor coverage ratios.

Stockholders Equity
Balance Sheet
-19.2%
$27.7M$22.4M

Equity decreased 19.2% — buybacks or losses reducing book value, monitor solvency ratios.

Net Income
P&L
+10.8%
-$43.7M-$39.0M

Net income grew 10.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-27
ADDED
and other applicable jurisdictions; the terms of the Company s credit facility; the Company s ability to successfully roll-out the Company s Better Me Provider Program on the planned timeline; and the Company s self-sustainability and existing cash balances.
The Company cautions investors not to place undue reliance on these forward-looking statements.
New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties.
(the Company or Neuronetics or the Registrant ) believes that mental health is as important as physical health.
As a global leader in neuroscience, the Company is delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.
The Company s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation ( TMS ), to create a pulsed, magnetic resonance imaging ( MRI )-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
) Food and Drug Administration (the FDA ) to treat adult patients with major depressive disorder ( MDD ) who have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode.
It is also cleared by the FDA to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression).
In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, we operate Greenbrook treatment centers ( Treatment Centers ) across the U.S., offering NeuroStar Advanced Therapy.
Greenbrook, a leading provider of mental healthcare services, is a wholly owned subsidiary of the Company.
REMOVED
and other applicable jurisdictions; the terms of the Company s credit facility; the Company s ability to successfully roll-out the Company s Better Me Provider program on the planned timeline; the Company s self-sustainability and existing cash balances; and the Company s ability to achieve cash flow break-even in the third quarter of 2025.
Business Overview We believe that mental health is as important as physical health.
As a global leader in neuroscience, we are delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.
Our first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation ( TMS ) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The system is cleared by the United States Food and Drug Administration (the FDA ) to treat adult patients with major depressive disorder ( MDD ) who have failed to achieve satisfactory improvement from at least one prior antidepressant medication in the current MDD episode.
It is also cleared by the FDA as an adjunct for adults with OCD, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression).
In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, we operate Greenbrook treatment centers ( Treatment Centers ) across the United States, offering NeuroStar Advanced Therapy ( Neurostar ).
The Company acquired Greenbrook, a leading provider of mental healthcare services, pursuant to an Arrangement Agreement effective as of December 9, 2024.
We believe we are the market leader in TMS therapy based on the estimated 195,356 global patients treated with over 7.1 million of our treatment sessions through December 31, 2024.
We generated revenues of $74.9 million for the year ended December 31, 2024.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →